You are here: Industry Insights > Lonza

News List

Lonza Completes Divestment of Sites to NextPharma contractpharma
April 02, 2021
Lonza exits both softgels and liquid-filled hard capsules and NextPharma plans to broaden its technology offering into lipid based finished dosage forms.
Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S. prnasia
April 01, 2021
Gracell Biotechnologies Inc. announced that the company has entered into a Manufacturing Service Agreement (MSA) with Lonza for clinical manufacturing of Gracell's FasTCAR-enabled CAR-T cell product candidates in the U.S.
Chime Biologics announces Marc Funk as new Board Director prnasia
March 22, 2021
Chime Biologics is pleased to announce the appointment of Marc Funk to its Board of Directors. Marc brings more than 20 years of leadership and industry experience in the global CDMO space.
Altimmune, Lonza Expand AdCOVID Manufacturing Pact contractpharma
March 15, 2021
Lonza to commission a dedicated suite for clinical and commercial supply of Altimmune’s COVID-19 vaccine candidate at its Houston facility.
Lonza Expands Solid Small Molecule Services contractpharma
February 18, 2021
To encompass all aspects of solid form screening and characterization of small molecule APIs.
Lonza to Divest Specialty Ingredients Biz contractpharma
February 10, 2021
Lonza has entered into a definitive agreement with Bain Capital and Cinven to to sell its Specialty Ingredients business and operations for an enterprise value of CHF 4.2 billion.
AMRI Makes Executive Move contractpharma
February 09, 2021
Albany Molecular Research, Inc. (AMRI), a global provider of advanced contract research, development and manufacturing solutions, has appointed Scott Waldman as senior vice president, corporate development.
Bain Capital, Cinven to acquire Lonza Specialty Ingredients for $4.7 billion expresspharma
February 09, 2021
Bain Capital and Cinven are acquiring Lonza’s Specialty Ingredients division in a deal worth $4.7 billion, the Swiss contract drug maker said.
Lonza Launches Cryopreserved Leukopaks contractpharma
January 29, 2021
Customizable cryopreserved Leukopaks aim to provide greater flexibility in immunology and cell therapy research.
Aruvant partners with Lonza to manufacture sickle cell disease treatment pharmaceutical-technology
January 20, 2021
Clinical-stage biopharmaceutical firm Aruvant Sciences and Lonza have entered a strategic long-term manufacturing agreement for the former’s one-time investigational gene therapy for sickle cell disease (SCD), ARU-1801.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page